Literature DB >> 500264

Pharmacokinetics of cefamandole in patients undergoing hemodialysis.

J A Campillo, J M Lanao, A Dominguez-Gil, J M Tabernero, F Rubio.   

Abstract

The pharmacokinetics of Cefamandole was studied in 17 patients with terminal renal impairment, 10 of which were undergoing sessions of hemodialysis while 7 were in the period between dialysis sessions. An open two-compartment kinetic model was used to describe the bi-phasic decrease of the plasma concentrations of Cefamandole thus establishing the amounts of the antibiotic in the peripheral and central compartments together with the amount eliminated. All patients received an i.v. bolus injections of 15 mg/kg body weight. During the hemodialysis sessions, the pharmacokinetic parameters of Cefamandole were the following: alpha = 5.006 hr-1 beta = 0.182 hr-1 K12 = 2.598 hr-1 K21 = 2.147 hr-1 K13 = 0.441 hr-1 Vc = 5.700 l Vp = 6.190 l Vdss = 11.94 l It may be seen that there is a decrease in the overall elimination constant compared with that obtained during the periods between the dialysis sessions. A dosage regimen of multiple doses is established as a function of the pharmacokinetic parameters of the antibiotic for patients with terminal renal impairment undergoing periodic sessions of hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 500264

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  3 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Pharmacokinetics of phosphomycin during haemofiltration.

Authors:  C Fernandez Lastra; E L Mariño; A Dominguez-Gil; J M Tabernero; J Grande Villoria
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

3.  Pharmacokinetics of cefoxitin during haemofiltration.

Authors:  M J Garcia; A Dominguez-Gil; J M Tabernero; M Diaz Molina
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.